结、直肠癌患者抑癌基因的甲基化检测

目的：评价特异性甲基化PCR（MSP）分析法检测抑癌基因高甲基化对结、直肠癌的诊疗价值。方法：应用MSP法检测36例结、直肠癌患者血清、术中癌旁组织及癌组织中的抑癌基因hMIM1、p15、p16甲基化的发生率。另选择36例健康体检者血清样品作正常对照。结果：36例结、直肠癌患者术前血清及术中癌组织的hMIM1、p15、p16甲基化发生率为59％-97％，癌旁组织略低；术后1周血清中hMIM1、p15、p16与术前比较明显下降（P〈0．01），而正常对照组抑癌基因甲基化发生率均为0。结论：MSP法的建立，直接检测结、直肠癌患者的抑癌基因的高甲基化状态，有助于临床判断和动态观察治疗的效果。

Clinical application of tumor suppressor genes methylation detection in colorectal cancer

Aim: To evaluate the clinical value of MSP(methylation specific PCR) in detection of tumor suppressor genes methylation in the colorectal cancer.Methods: The prevalence of methylated tumor suppressor genes(hMLH1,p15,p16) were evaluated in 36 colorectal cancer patients by MSP method in serums and the para-cancerous and cancerous tissue samples obtained at operation,and 36 serum samples obtained from healthy people as normal control.Results: The prevalence study of methylated tumor suppressor genes(hMLH1,p15,p16) in serums and cancerous tissue samples obtained from 36 colorectal cancer patients showed a percentage of 59% to 97%(the samples were obtained pre-op and during operation respectively).The para-canceroustissue samples has a slightly lower percentage.There's an obvious drop of the hMLH1,p15,p16 in the serums obtained from 1 week post-operation patients,but the control group's has a 0% prevalence rate.Conclusion: The MSP method,which directly tests the colorectal cancer patient's methylated cancer suppressor genes,is a valuable tool in clinical judgment of therapeutic effect.